Insmed Inc’s recent filing unveils that its Officer Bonstein Sara acquired Company’s shares for reported $5.88 million on Jun 23 ’25. In the deal valued at $101.75 per share,57,765 shares were bought.
Then, Wise John Drayton bought 20,000 shares, generating $2,099,400 in total proceeds.
Before that, Lewis William sold 129,805 shares. Insmed Inc shares valued at $13,031,681 were divested by the Chair and CEO at a price of $100.39 per share. As a result of the transaction, Lewis William now holds 233,924 shares, worth roughly $24.66 million.
Jefferies initiated its Insmed Inc [INSM] rating to a Buy in a research note published on May 13, 2025; the price target was $105. A number of analysts have revised their coverage, including RBC Capital Mkts’s analysts, who began to cover the stock in late February with a ‘”an Outperform”‘ rating. Truist began covering INSM with “Buy” recommendation on April 23, 2024. Wolfe Research started covering the stock on February 15, 2024. It rated INSM as “an Outperform”.
Price Performance Review of INSM
On Monday, Insmed Inc [NASDAQ:INSM] saw its stock jump 2.67%% to $105.42. Over the last five days, the stock has gained 6.78%. Insmed Inc shares have risen nearly 60.75% since the year began. Nevertheless, the stocks have risen 52.69% over the past one year. While a 52-week high of $102.81 was reached on 06/23/25, a 52-week low of $60.40 was recorded on 04/09/25.
Levels Of Support And Resistance For INSM Stock
The 24-hour chart illustrates a support level at 102.48, which if violated will result in even more drops to 99.54. On the upside, there is a resistance level at 106.92. A further resistance level may holdings at 108.42.
How much short interest is there in Insmed Inc?
A steep rise in short interest was recorded in Insmed Inc stocks on 2025-05-30, growing by 1.68 million shares to a total of 17.46 million shares. Yahoo Finance data shows the prior-month short interest on 2025-04-30 was 15.78 million shares. There was a rise of 9.62%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on December 08, 2023 when Wells Fargo began covering the stock and recommended ‘”an Overweight”‘ rating along with a $55 price target.
